Danish biotech Genmab hit by ending of trial using key cancer drug
COPENHAGEN (Reuters) – Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug. Genmab said Janssen, a Johnson & Johnson business, had decided that t... More »
